New York, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Endoscopic Submucosal Dissection Market by Product, Indication, End ...

New York, United States, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The Global Endoscopic Submucosal Dissection Market Size is expected to reach USD 542.38 Million By 2032, at a CAGR of 5.4% during the ...

A prospective clinical trial from researchers in Japan shows magnetic-anchor-guided endoscopic submucosal dissection for large early gastric cancer to be a feasible and safe method in humans.

The "Endoscopic Submucosal Dissection Market - A Global and Regional Analysis: Focus on Indication, Product, End user, Country, and Region - Analysis and Forecast, 2025-2035" has been added to ...

DELRAY BEACH, Fla., Aug. 27, 2025 /PRNewswire/ -- The global Endoscopic Submucosal Dissection Market, valued at US$0.46 billion in 2024, stood at US$0.50 billion in 2025 and is projected to advance at ...

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) ...

Endoscopic submucosal dissection (ESD) of large colorectal adenomas resulted in a lower recurrence rate compared with endoscopic mucosal resection (EMR), but the more technically complex ESD had a ...

Safety and efficacy of combining genotype-guided irinotecan (Iri) with 5FU, leucovorin (LV), oxaliplatin (Ox), and docetaxel (Tax) (gFOLFOXIRITAX): The I-FLOAT phase 1 dose-escalation study for ...

Gastric lesions include benign, dysplastic, and malignant tumours. Patients may be asymptomatic or experience loss of appetite and weight, anaemia and abdominal discomfort or pain. The procedure is ...